Hari Madhav

New Delhi, DL 110025, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Development of substituted 2-(4-(sulfonyl)piperazin-1-yl)quinazoline molecular hybrids as a new class of antimalarials.

Development of substituted 2-(4-(sulfonyl)piperazin-1-yl)quinazoline molecular hybrids as a new class of antimalarials.

Journal: RSC advances

Published: November 05, 2025

Identifying thiourea-based hybrids of quinazoline and oxospirochromane as inhibitors of Plasmodium cysteine proteases arresting the parasitic growth at the early trophozoite stage.

Identifying thiourea-based hybrids of quinazoline and oxospirochromane as inhibitors of Plasmodium cysteine proteases arresting the parasitic growth at the early trophozoite stage.

Journal: Bioorganic & medicinal chemistry letters

Published: January 03, 2025

Reinvestigation of diphenylmethylpiperazine analogues of pyrazine as new class of Plasmodial cysteine protease inhibitors for the treatment of malaria.

Reinvestigation of diphenylmethylpiperazine analogues of pyrazine as new class of Plasmodial cysteine protease inhibitors for the treatment of malaria.

Journal: RSC medicinal chemistry

Published: September 12, 2023

Naphthyl bearing 1,3,4-thiadiazoleacetamides targeting the parasitic folate pathway as anti-infectious agents: in silico, synthesis, and biological approach.

Naphthyl bearing 1,3,4-thiadiazoleacetamides targeting the parasitic folate pathway as anti-infectious agents: in silico, synthesis, and biological approach.

Journal: RSC medicinal chemistry

Published: August 20, 2023

Development of diphenylmethylpiperazine hybrids of chloroquinoline and triazolopyrimidine using Petasis reaction as new cysteine proteases inhibitors for malaria therapeutics.

Development of diphenylmethylpiperazine hybrids of chloroquinoline and triazolopyrimidine using Petasis reaction as new cysteine proteases inhibitors for malaria therapeutics.

Journal: European journal of medicinal chemistry

Published: May 14, 2023

Identification of new oxospiro chromane quinoline-carboxylate antimalarials that arrest parasite growth at ring stage.

Identification of new oxospiro chromane quinoline-carboxylate antimalarials that arrest parasite growth at ring stage.

Journal: Journal of biomolecular structure & dynamics

Published: March 27, 2023

Design, synthesis, and biological evaluation of morpholinopyrimidine derivatives as anti-inflammatory agents.

Design, synthesis, and biological evaluation of morpholinopyrimidine derivatives as anti-inflammatory agents.

Journal: RSC advances

Published: March 23, 2023

Multicomponent Petasis reaction for the identification of pyrazine based multi-target directed anti-Alzheimer's agents: In-silico design, synthesis, and characterization.

Multicomponent Petasis reaction for the identification of pyrazine based multi-target directed anti-Alzheimer's agents: In-silico design, synthesis, and characterization.

Journal: European journal of medicinal chemistry

Published: February 01, 2023

Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics.

Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics.

Journal: RSC medicinal chemistry

Published: December 25, 2021

An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.

An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.

Journal: European journal of medicinal chemistry

Published: July 03, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026